Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms

Model scores of the 29,894 trials active now.

Model score 17% for any early termination, 7% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2024-03-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: recurrentpatientradiationprimarypet
  Phrases that lowered it: participantslesionsusedevaluationpatients who
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Drug's FAERS reports with a death: 7.7% (lowers risk) · Drug's FDA history
• Responsible party: sponsor investigator (raises risk) · Design
• Design: parallel (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 3 (raises risk) · Sponsor's track record
• Disease area, neurology: Yes (raises risk) · Disease area
• Primary purpose: diagnostic (lowers risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Drug's FAERS reports marked serious: 77.4% (lowers risk) · Drug's FDA history
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Maximum age: not given (raises risk) · Who can join
• Number of arms: 2 (raises risk) · Design
• Sponsor's past trials: 1 (raises risk) · Sponsor's track record
• Minimum age: 3 (lowers risk) · Who can join
• Blinding: none (raises risk) · Design
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Multi-Tracer PET Assessment of Primary Brain Tumors NCT00813566 · started 2010 · scored riskier than 93% of active trials completed
• [18F]Fluciclovine and [18F]FLT PET/CT Assessment of Primary High-Grade Brain Tumors NCT03276676 · started 2018 · scored riskier than 92% of active trials terminated
• A Pilot Study of 18F-FLT in Pediatric Patients With Central Nervous System (CNS) Tumors NCT00633958 · started 2008 · scored riskier than 36% of active trials terminated
• PET Imaging of Intracranial Cancers With 18F-FSPG NCT02370563 · started 2014 · scored riskier than 65% of active trials terminated
• Assessment of Primary and Metastatic Brain Tumor Hypoxia With Fluoromisonidazole, FDG and Water NCT01246869 · started 2013 · scored riskier than 96% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.